Discover and read the best of Twitter Threads about #ACR21
Most recents (4)
#ACR22 epidemiology posters 
Abs 0700 @zach_wallace_md
💻Using NLP, ML algorithms to identify ANCA vasculitis cases
They also looked at the difference in performance metrics with/without filtering keywords
An explosion of NLP studies in rheum! #ACR22
💻Using NLP, ML algorithms to identify ANCA vasculitis cases
They also looked at the difference in performance metrics with/without filtering keywords
An explosion of NLP studies in rheum! #ACR22
@zach_wallace_md Abs 0732 Ho, et al. @JYazdanyMD @MilenaGianfran
💻Part of the explosion of NLP studies in rheum
Here the UCSF group aimed to capture VZV cases (differentiate from vaccination); and to capture active vs historical cases
See their diagrams explaining the steps!
#ACR22
💻Part of the explosion of NLP studies in rheum
Here the UCSF group aimed to capture VZV cases (differentiate from vaccination); and to capture active vs historical cases
See their diagrams explaining the steps!
#ACR22
@SattuiSEMD 🌟Abs 2191 Choi, et al
Korean health insurance data with mother/child linkage
❓Research Q: What the risk of several outcomes in children born to mothers with SLE?
🤰Mothers: prevalent or incident SLE at delivery
👶Outcomes in children
#ACR22
Korean health insurance data with mother/child linkage
❓Research Q: What the risk of several outcomes in children born to mothers with SLE?
🤰Mothers: prevalent or incident SLE at delivery
👶Outcomes in children
#ACR22
@SattuiSEMD Abs 2191 cont'd
Risk in children:
>SLE HR 98 (!)
>other autoimmune disease HR 1.26
>neurodevelopmental disorders HR 1.35
🤔The HR of 98 suggests an issue with small cells (few events)
#ACR22
Risk in children:
>SLE HR 98 (!)
>other autoimmune disease HR 1.26
>neurodevelopmental disorders HR 1.35
🤔The HR of 98 suggests an issue with small cells (few events)
#ACR22
🌟Abs 2215 Solomon, et al.
RCT of n=115 with RA on RTX
❓Does adding TNFi vs DMARD triple therapy reduce arterial inflammation assessed on FDG-PET/CT? 💓⚡
#ACR22
RCT of n=115 with RA on RTX
❓Does adding TNFi vs DMARD triple therapy reduce arterial inflammation assessed on FDG-PET/CT? 💓⚡
#ACR22
Abs 2215 cont'd
Both tx arms: ⬇arterial inflammation on PET/CT
🔹But, no difference between groups
🔹And, no correlation of arterial inflammation measure with change in DAS28 disease activity
#ACR22
Both tx arms: ⬇arterial inflammation on PET/CT
🔹But, no difference between groups
🔹And, no correlation of arterial inflammation measure with change in DAS28 disease activity
#ACR22
One of the most upvoted comments on my #ACR21 plenary was "Why are we still doing observational studies on risks of #steroidsinRA? Given unavoidable confounding, shouldn't we just focus on clinical trials?" I responded in-platform, but thought the topic called for a🧵also. 1/
First of all, clinical trials on this topic are very important, and, when well-designed, will almost always yield results more reliable than those of observational studies when powered to look at common, short-term steroid side effects. 2/
However, many steroid-associated AEs are low-prevalence & require long-term followup to detect. MACE, major fractures, sepsis, VTE, etc. It would be very difficult to power an RCT to reliably assess effect of steroid use (esp. low-dose) on these outcomes. 3/
